Busulfan

證據等級: L5

預測適應症: 10 個

Busulfan: From Chronic Myeloid Leukemia to Myelodysplastic Syndrome

One-Sentence Summary

Busulfan is a bifunctional alkylating agent historically used for chronic myeloid leukemia (CML) and established as a cornerstone myeloablative conditioning drug before allogeneic hematopoietic stem cell transplantation (HSCT). The TxGNN model predicts it may be effective for Myelodysplastic Syndrome (MDS), with 40+ clinical trials identified — including multiple completed Phase 2 and Phase 3 studies — supporting its role as a conditioning component in MDS patients undergoing allo-HSCT, though no PubMed literature was retrieved for this specific indication pairing.

Quick Overview

Item	Content
Original Indication	Chronic myeloid leukemia / HSCT conditioning (Taiwan TFDA data unavailable)
Predicted New Indication	Myelodysplastic Syndrome (MDS)
TxGNN Prediction Score	99.62%
Evidence Level	L2
Taiwan Market Status	Not marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the Evidence Pack. Based on established pharmacology, Busulfan is a bifunctional alkylating agent of the alkylsulfonate class. It cross-links DNA strands via alkylation of guanine bases, selectively destroying rapidly dividing hematopoietic progenitor cells. This makes it particularly suited for bone marrow clearance before donor stem cell engraftment.

Busulfan has been a cornerstone of HSCT conditioning for decades, primarily in AML and CML. Common regimens include Bu+Cy (BUCY), Bu+Flu (BuFlu), and Bu+Mel+Flu, each designed to eradicate abnormal host hematopoiesis and suppress immune rejection of the graft. Pharmacokinetic-guided dosing (TDM) has further optimized therapeutic window management for this drug.

MDS is a clonal disorder of hematopoietic stem cells characterized by dysplastic and ineffective blood cell production, with a subset progressing to AML. Allogeneic HSCT remains the only potentially curative treatment for intermediate- to high-risk MDS. Since Busulfan’s therapeutic target — the aberrant bone marrow stem cell compartment — is identical in both CML conditioning and MDS, the TxGNN prediction is mechanistically coherent and clinically well-grounded. Multiple Phase 2 and Phase 3 trials have already validated Busulfan-containing conditioning in MDS patients across diverse combinations and intensity levels.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00469144	Phase 3	Completed	233	Randomized trial comparing PK-guided versus fixed-dose IV busulfan with fludarabine for AML/MDS; assessed whether individualized dosing improves efficacy and reduces toxicity
NCT00629798	Phase 2	Completed	64	Bu+Mel+Flu with peri-transplant palifermin for advanced MDS and AML receiving T-cell depleted HSCT; tested gastrointestinal mucosal protection alongside conditioning
NCT00301834	Phase 2	Completed	35	Bu+Flu+Alemtuzumab reduced-toxicity regimen specifically targeting pediatric MDS, marrow failure syndromes, and stem cell defects; full safety and efficacy evaluation
NCT06829472	Phase 3	Recruiting	120	Randomized comparison of melphalan 100 vs 140 mg/m² within Mel-Bu-Flu (MBF) conditioning for AML/MDS; aimed at preserving low relapse while reducing toxicity
NCT04713956	Phase 2/3	Unknown	242	Head-to-head comparison of G-CSF+DAC+BUCY versus G-CSF+DAC+BF for MDS (RAEB-1, RAEB-2) and secondary AML undergoing allo-HSCT
NCT05823714	Phase 2	Unknown	70	Novel bridging strategy: venetoclax+azacitidine induction followed by modified BUCY conditioning for high-risk MDS/AML; evaluates efficacy and safety of sequential approach
NCT03412409	Phase 2	Recruiting	50	Reduced-intensity conditioning for elderly or high-comorbidity MDS patients undergoing haploidentical HSCT; addresses underserved population with limited transplant tolerance
NCT06247917	Phase 2	Unknown	59	FLU-BU-MEL conditioning for allo-HSCT in untreated intermediate/high-risk MDS-EB; direct single-arm prospective evaluation of triple-drug combination
NCT02793544	Phase 2	Completed	80	Multicenter trial of HLA-mismatched unrelated donor BMT with post-transplant cyclophosphamide for hematologic malignancies including MDS; busulfan included as conditioning option
NCT00453206	NA	Completed	66	Reduced-intensity conditioning with fludarabine, busulfan, and melphalan for broad hematological diseases including MDS; demonstrated feasibility across mixed-diagnosis cohort

Literature Evidence

Currently no related literature available for this indication pairing from the evidence database.

Taiwan Market Information

Busulfan is currently not marketed in Taiwan (0 TFDA authorizations). The drug is approved internationally — Busilvex® (IV busulfan, Pierre Fabre) holds EMA authorization in the EU, and Busulfex® is approved in the United States — both primarily as conditioning regimens before HSCT. A formal TFDA approval pathway or special import arrangement would be required for use in Taiwan.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Conventional cytotoxic (Alkylating agent – alkylsulfonate class; bifunctional DNA cross-linker)
Myelosuppression Risk	High — myeloablation is the intended therapeutic mechanism; profound and prolonged pancytopenia is expected and required for engraftment
Emetogenicity Classification	Low to moderate (IV formulation); standard antiemetic prophylaxis recommended
Monitoring Items	CBC with differential (serial), busulfan serum pharmacokinetics (TDM; target AUC 900–1350 µmol·min/L), liver function tests (hepatic veno-occlusive disease / sinusoidal obstruction syndrome risk), renal function, pulmonary function (busulfan-induced pulmonary fibrosis risk with prolonged use)
Handling Protection	Must follow cytotoxic drug handling regulations; IV preparation requires closed-system transfer devices (CSTD) and appropriate PPE per institutional pharmacy protocol

Safety Considerations

Please refer to the SmPC for safety information.

Note: Taiwan TFDA package insert data (key warnings, contraindications, and drug interaction profile) was not available at the time of this report generation. This is classified as a Blocking data gap. Safety assessment should be based on the EMA Summary of Product Characteristics (SmPC) for Busilvex® or the US FDA label for Busulfex® until TFDA documentation is retrieved.

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: Multiple completed Phase 2 trials and at least one large completed Phase 3 trial (NCT00469144, n=233) have evaluated Busulfan-containing conditioning regimens specifically in MDS patients, demonstrating clinical feasibility and acceptable safety profiles across multiple combination strategies (BuCy, BuFluMel, modified BUCY, and BuFlu). The mechanistic rationale — ablating dysplastic hematopoietic stem cells to enable donor engraftment — directly maps to MDS pathophysiology, making this prediction biologically and clinically sound. However, Busulfan is not currently marketed in Taiwan, which represents a significant regulatory barrier before clinical application.

To proceed, the following is needed:

Regulatory pathway: Establish TFDA special import or approval process for Busulfan (currently 0 Taiwan authorizations)
Safety documentation: Retrieve Taiwan TFDA package insert or equivalent SmPC to complete safety assessment (key warnings, contraindications, DDI profile)
PK/TDM protocol: Implement pharmacokinetic-guided dosing (target AUC monitoring) to optimize therapeutic window and reduce toxicity
Patient selection framework: Define eligibility based on MDS subtype (RAEB-1, RAEB-2), IPSS-R risk score, age, comorbidity burden, and availability of suitable allogeneic donor
Institutional readiness: Confirm availability of allogeneic HSCT infrastructure including HLA typing, GVHD prophylaxis protocols, and post-transplant monitoring capacity
Literature gap: Conduct targeted PubMed search with broader MeSH terms to retrieve existing systematic reviews and registry data on Busulfan conditioning outcomes in MDS
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.